earnings
confidence high
sentiment positive
materiality 0.78
Catalyst Q1 revenues $141.4M (+43.6% YoY); GAAP EPS $0.45; reaffirms FY outlook
CATALYST PHARMACEUTICALS, INC.
2025-Q1 EPS reported
$0.45
revenue$141,421,000
- Total product revenue $141.4M, up 43.6% YoY; FIRDAPSE $83.7M (+25.3%), AGAMREE $22.0M (from $1.2M).
- GAAP net income $56.7M ($0.45 diluted EPS); Non-GAAP net income $86.6M ($0.68 diluted EPS).
- Cash and equivalents $580.7M as of March 31, 2025; no debt.
- Reaffirms full-year 2025 total revenue guidance of $545M–$565M.
- AGAMREE commercial launch momentum with 1,777.5% YoY revenue growth.